About Pharmacelsus
Pharmacelsus is a Healthcare company based in Saarbrucken (Germany) founded in 2000, and was acquired by GBA Group in February 2017. Hit-to-lead and lead optimization services in steroid endocrinology are offered. Pharmacelsus offers products and services including In-Vitro-ADME, In-Vivo-DMPK, and Toxicology Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is Pharmacelsus GmbH.
Company details
Pharmacelsus was founded in 2000 as a preclinical contract research organization based in Saarbrucken, Germany. Services provided include in vitro ADME, in vivo DMPK, toxicology, and bioanalytical assays using UHPLC-MSMS and LC-MSMS. In vitro and in vivo pharmacology studies are conducted for conditions such as diabetes, fibrosis, cancer, and non-alcoholic fatty liver disease. Expertise in steroid endocrinology is applied through various screening models for safety and efficacy.
- Headquarters Saarbrucken, Germany
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pharmacelsus.com
- Social LinkedIn YouTube
- Acquired by GBA Group (Feb 2017)
- Legal Name Pharmacelsus Gmbh
Products & Services of Pharmacelsus
Pharmacelsus offers a comprehensive portfolio of products and services, including In-Vitro-ADME, In-Vivo-DMPK, and Toxicology Services.
Services for absorption, distribution, metabolism, and excretion in drug development
In vivo services for drug metabolism and pharmacokinetics analysis
Testing for toxicity in preclinical drug research and development
Apps and channels of Pharmacelsus
its YouTube channel GBA Group has 94 subscribers and 30 videos.
Videos from Pharmacelsus
The most watched videos on Pharmacelsus's YouTube channel, GBA Group (94 subscribers). Click a video to play it here.
More on GBA Group.
Investors in Pharmacelsus
Pharmacelsus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GBA Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
GBA Group is recognized as a leading life sciences service provider. | 1975 | gba-group.com | Hamburg, Germany |
Investor details for Pharmacelsus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Pharmacelsus
2 dated milestones of Pharmacelsus across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Pharmacelsus is founded.
- Exit Acquired by GBA Group.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pharmacelsus
Pharmacelsus was founded in 2000.
Pharmacelsus is headquartered in Saarbrucken, Germany. It is registered at Saarbrucken, Saarland, Germany.
Pharmacelsus was founded in 2000 as a preclinical contract research organization based in Saarbrucken, Germany. Services provided include in vitro ADME, in vivo DMPK, toxicology, and bioanalytical assays using UHPLC-MSMS and LC-MSMS. In vitro and in vivo pharmacology studies are conducted for conditions such as diabetes, fibrosis, cancer, and non-alcoholic fatty liver disease. Expertise in steroid endocrinology is applied through various screening models for safety and efficacy.
Pharmacelsus offers In-Vitro-ADME, In-Vivo-DMPK, and Toxicology Services.
Pharmacelsus has 1 investor. Key investors include GBA Group.
Pharmacelsus operates through Pharmacelsus Gmbh.
Yes. Pharmacelsus was acquired by GBA Group in February 2017.